Literature DB >> 6127137

Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

M J Dew, P Hughes, A D Harries, G Williams, B K Evans, J Rhodes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6127137      PMCID： PMC1500334          DOI： 10.1136/bmj.285.6347.1012

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  2 in total

1.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

2.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335
  2 in total
  41 in total

1.  Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

Authors:  R A van Hogezand; H M Kennis; A van Schaik; J P Koopman; P A van Hees; J H van Tongeren
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Acute pancreatitis during oral 5-aminosalicylic acid therapy.

Authors:  M T Fiorentini; M Fracchia; G Galatola; A Barlotta; M de la Pierre
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

Review 3.  Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis.

Authors:  E Adachi; K Okazaki; Y Matsushima; H Seno; K Uchida; H Nakase; C Kawanami; T Nakamura; T Chiba
Journal:  Int J Pancreatol       Date:  1999-06

4.  Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease.

Authors:  C Brignola; P Iannone; S Pasquali; M Campieri; P Gionchetti; A Belluzzi; O Basso; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Which component of sulphasalazine is active in rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

8.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

9.  Salicylate induced exacerbation of ulcerative colitis.

Authors:  T K Chakraborty; D Bhatia; R C Heading; M J Ford
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

10.  Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.

Authors:  M J Dew; P Ebden; N S Kidwai; G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.